Hansa Biopharma Ab Stock Net Asset
HNSBF Stock | USD 2.93 0.00 0.00% |
Hansa Biopharma AB fundamentals help investors to digest information that contributes to Hansa Biopharma's financial success or failures. It also enables traders to predict the movement of Hansa Pink Sheet. The fundamental analysis module provides a way to measure Hansa Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hansa Biopharma pink sheet.
Hansa |
Hansa Biopharma AB Company Net Asset Analysis
Hansa Biopharma's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Hansa Biopharma Net Asset | 1.01 B |
Most of Hansa Biopharma's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
Competition |
Based on the recorded statements, Hansa Biopharma AB has a Net Asset of 1.01 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The net asset for all United States stocks is notably lower than that of the firm.
Hansa Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hansa Biopharma's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hansa Biopharma could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics of similar companies.Hansa Biopharma is currently under evaluation in net asset category among related companies.
Hansa Fundamentals
Return On Equity | -0.89 | |||
Return On Asset | -0.27 | |||
Current Valuation | 189.89 M | |||
Shares Outstanding | 52.44 M | |||
Shares Owned By Insiders | 7.37 % | |||
Shares Owned By Institutions | 41.33 % | |||
Price To Earning | (46.57) X | |||
Price To Book | 6.59 X | |||
Price To Sales | 16.29 X | |||
Revenue | 33.88 M | |||
Gross Profit | 116.05 M | |||
EBITDA | (538.83 M) | |||
Net Income | (548.28 M) | |||
Cash And Equivalents | 60.15 M | |||
Cash Per Share | 1.58 X | |||
Debt To Equity | 2.29 % | |||
Current Ratio | 6.42 X | |||
Book Value Per Share | 1.50 X | |||
Cash Flow From Operations | (481.17 M) | |||
Earnings Per Share | (0.65) X | |||
Number Of Employees | 150 | |||
Beta | 0.88 | |||
Market Capitalization | 274.8 M | |||
Total Asset | 1.01 B | |||
Working Capital | 86 M | |||
Current Asset | 105 M | |||
Current Liabilities | 19 M | |||
Net Asset | 1.01 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Complementary Tools for Hansa Pink Sheet analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Stocks Directory Find actively traded stocks across global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |